| pubmed-article:1627816 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1627816 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:1627816 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:1627816 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:1627816 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:1627816 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:1627816 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:1627816 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1627816 | pubmed:dateCreated | 1992-8-20 | lld:pubmed |
| pubmed-article:1627816 | pubmed:abstractText | Weekly low dose mitoxantrone (3 mg/m2) plus doxorubicin (8 mg/m2) was administered as second-line chemotherapy to 33 patients with advanced breast cancer. Four out of 28 evaluable patients (14%) obtained a partial response with a median duration of 34 weeks (range 18-67+ weeks), while 8 patients (29%) showed stable disease with a median duration of 28 weeks (range 11+-60 weeks). Gastrointestinal toxicity and alopecia were mild. Grade II and III leukopenia occurred in 63% of the courses without serious infectious disease. Four patients experienced an asymptomatic drop of 16-20% in the left ventricular ejection fraction (LVEF) after relatively low cumulative doses of each drug, and one patient with a history of pericarditis carcinomatosa and mediastinal irradiation developed a heart failure. In conclusion, this second-line combination treatment had moderate activity in breast cancer and caused only few subjective side effects, especially with respect to gastrointestinal symptoms. | lld:pubmed |
| pubmed-article:1627816 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1627816 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1627816 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1627816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1627816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1627816 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1627816 | pubmed:issn | 0167-6806 | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:KlijnJ GJG | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:DeenDD | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:Alexieva-Figu... | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:van PuttenW... | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:PlantingA SAS | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:RodenburgC... | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:VerweijJJ | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:BontenbalMM | lld:pubmed |
| pubmed-article:1627816 | pubmed:author | pubmed-author:BartelsC CCC | lld:pubmed |
| pubmed-article:1627816 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1627816 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:1627816 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1627816 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1627816 | pubmed:pagination | 133-8 | lld:pubmed |
| pubmed-article:1627816 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:meshHeading | pubmed-meshheading:1627816-... | lld:pubmed |
| pubmed-article:1627816 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1627816 | pubmed:articleTitle | Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer. | lld:pubmed |
| pubmed-article:1627816 | pubmed:affiliation | Department of Medical Oncology, Rotterdam Cancer Institute (Dr Daniel den Hoed Cancer Center), The Netherlands. | lld:pubmed |
| pubmed-article:1627816 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1627816 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1627816 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
